GAVISCON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GAVISCON (GAVISCON).
Gaviscon forms a protective alginate raft on top of gastric contents, providing a physical barrier that prevents reflux of gastric acid into the esophagus. The alginate reacts with gastric acid to form a gel-like foam that floats on the stomach contents. Gaviscon also contains antacids (calcium carbonate and sodium bicarbonate) that neutralize gastric acid.
| Metabolism | Gaviscon components are not significantly metabolized; they act locally in the stomach. The antacids may partially dissociate and be absorbed minimally, but systemic metabolism is negligible. |
| Excretion | Primarily fecal as insoluble alginate rafts; minimal renal elimination (<1%) as absorbed components (sodium, potassium, calcium) excreted in urine. |
| Half-life | Not applicable; Gaviscon acts locally in the stomach without systemic absorption of active ingredients. The alginate raft persists for 2-4 hours post-dose. |
| Protein binding | Negligible (<1%) due to minimal systemic absorption; alginate and antacids not significantly protein-bound. |
| Volume of Distribution | Not applicable; components act locally in the GI tract without systemic distribution. |
| Bioavailability | Not relevant; alginate and antacids exert local effect without systemic absorption. |
| Onset of Action | Oral: 3-5 minutes for raft formation and symptom relief. |
| Duration of Action | 2-4 hours, depending on meal volume and gastric emptying; may be extended postprandially. |
10-20 mL orally after meals and at bedtime, maximum 80 mL/day
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | No dose adjustment required; use with caution in severe renal impairment due to sodium and aluminum content |
| Liver impairment | No dose adjustment required |
| Pediatric use | Children 2-12 years: 5-10 mL orally after meals and at bedtime; maximum 40 mL/day. Children under 2 years: not recommended |
| Geriatric use | No specific dose adjustment; monitor for adverse effects due to potential polypharmacy and comorbidities |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GAVISCON (GAVISCON).
| Breastfeeding | Gaviscon components are minimally absorbed systemically and unlikely to reach significant levels in breast milk. Aluminum and magnesium salts have limited transfer; M/P ratio not established. Considered compatible with breastfeeding by most guidelines (e.g., WHO, AAP). Use with caution in neonates with renal impairment due to potential aluminum accumulation. Avoid high doses to prevent maternal electrolyte disturbances that could affect milk composition. |
| Teratogenic Risk | Gaviscon (alginic acid, aluminum hydroxide, magnesium carbonate, sodium bicarbonate) is considered low risk in pregnancy. Animal studies show no evidence of teratogenicity. However, high doses of aluminum hydroxide may accumulate and theoretically cause fetal osteomalacia, but this is not clinically relevant at recommended doses. Sodium content may contribute to fluid overload in preeclampsia or cardiac conditions. No known specific trimester risks; generally avoid high doses in first trimester if possible, but data are limited. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to any component","Phenylketonuria (contains aspartame in some formulations)","Severe renal impairment (due to sodium and aluminum content)","Hypocalcemia or conditions predisposing to hypercalcemia (e.g., sarcoidosis, malignancy)"]
| Precautions | ["Contains sodium bicarbonate; may cause sodium overload in patients with hypertension, congestive heart failure, or renal impairment.","Contains calcium carbonate; excessive use may lead to hypercalcemia, especially in renal impairment.","Avoid use in patients with renal insufficiency due to risk of aluminum (from alginate) accumulation (though alginate contains minimal aluminum).","May interfere with absorption of other medications; separate administration by at least 2 hours.","Not for prolonged use (>2 weeks) without medical evaluation."] |
Loading safety data…
| Fetal Monitoring | No specific mandatory monitoring. In patients with preeclampsia, cardiac disease, or renal insufficiency, monitor for fluid overload and electrolyte imbalances (sodium load). Fetal growth and amniotic fluid volume not affected. If prolonged high-dose use, consider monitoring maternal serum calcium, magnesium, and aluminum levels (rare). |
| Fertility Effects | No known adverse effects on fertility. Antacids like Gaviscon do not interfere with normal reproductive hormone function. No evidence of reduced fertility in humans or animals. |